All In MedTech

FDA Clearance Tracker · P990053-S009

OXI FIRST FETAL OXYGEN SATURATION MONITORING SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 25, 2002 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 25, 2002

Approved

Time to decision

222 days

Received Apr 17, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990053-S009
Device name
OXI FIRST FETAL OXYGEN SATURATION MONITORING SYSTEM
Applicant
Covidien, LLC
Applicant location
Boulder, CO
Received
Apr 17, 2002
Decided
Nov 25, 2002
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P990053

Device type

Device class
Class III

Every decision under product code MMA

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A NEW MANUFACTURING FACILITY LOCATED AT NELLCOR PURITAN BENNETT, INC., MINNEAPOLIS, MINNESOTA. THIS FACILITY WILL PERFORM MANUFACTURING OF THE FSP02-PM FETAL PATIENT MODULES.

Source documents

Other decisions for Covidien, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.